Global LowGrade Glioma Trends 2025, Forecast To 2034
26 Mar, 2025
What Fueled The Previous Growth In The LowGrade Glioma Market?
The lowgrade glioma market has seen considerable growth due to a variety of factors.
• The market for low-grade gliomas has experienced solid growth in the past few years. With an expansion from $1.39 billion in 2024 to $1.48 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.1%.
The contributing factors to this growth during the historical period can be linked to an escalation in awareness surrounding brain tumors, increased investment in oncological research, growth in the assignment of orphan drug designations, the broadening of telemedicine, and enhanced access to healthcare services.
How Does the Forecast Look for the LowGrade Glioma Market?
The lowgrade glioma market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for low-grade glioma is predicted to experience significant growth in the coming years, reaching $1.86 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 5.9%.
The expansion in the forecasted period is primarily due to an increasing elderly population, elevated healthcare spending, an escalation in the frequency of brain tumors, expanded government programs, and a rise in the occurrence and frequency of high-grade gliomas. Key trends anticipated during the forecast period involve progress in imaging technology, evolution of radiation therapy methods, the introduction of new chemotherapy protocols, the growth of clinical trials, and the incorporation of immunotherapy.
What Are The Leading Drivers Of Growth In The LowGrade Glioma Market?
The surge in brain tumor occurrences is anticipated to aid the expansion of the low-grade glioma market. Brain tumors, which can be either benign or malignant, are unusual cell growths in the brain or nearby regions. The increased prevalence is ascribed to factors like more exposure to radiation, pollution, genetic susceptibility, and the aging process. Low-grade glioma proves to be beneficial in dealing with brain tumors by employing advanced diagnostic methods and targeted treatments such as surgery, radiation, and chemotherapy. These treatments aid in slowing down the growth of the tumor, preserving neurological function and enhancing patient outcomes, hence early detection and tailored treatment are vital for managing other brain tumors of similar growth patterns. As an example, in October 2023, The Central Brain Tumor Registry of the United States (CBTRUS), a non-profit organization based in the US, reported that in 2022, the global incidences of malignant brain tumors were approximately 3.5 in 100,000, with wealthier countries (4.9 in 100,000) having higher rates compared to lower-middle (2.4 in 100,000) and poorer nations. Consequently, this increase in brain tumors is propelling the low-grade glioma market's expansion.
How Are The Segments Defined Within The Global LowGrade Glioma Market?
The low-grade glioma market covered in this report is segmented –
1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Route Of Administration: Topical, Oral
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
What Emerging Trends Are Influencing The Growth Of The LowGrade Glioma Market?
Large firms active in the low-grade glioma market are concentrating their efforts on optimizing combination therapies and targeted treatments like genetic alteration medication. These are designed to alter or disrupt specific genetic mutations in cells, delivering treatment to conditions such as cancer by obstructing the routes that lead to unchecked cellular proliferation. For example, Day One Biopharmaceuticals, an American-based biotech firm, in May 2024, introduced Tovorafenib (Ojemda) following fast-tracked FDA approval. This specially designed therapy is tailored for children six months and above who have low-grade glioma (LGG) cases that are either irreparable or recurrent and have BRAF gene alterations. The therapy, which is administered orally once a week, fills a significant void for pediatric LGG patients who have previously had inadequate treatment options.
Who Are the Key Players In The LowGrade Glioma Market?
Major companies operating in the low-grade glioma market are:
• McKesson Corporation
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• Daiichi Sankyo Company Limited
• Ipsen S.A.
• BeiGene Ltd.
• NovoCure Limited
• Les Laboratoires Servier
• Day One Biopharmaceuticals Inc.
• CStone Pharmaceuticals Co. Ltd.
• AnHeart Therapeutics Inc.
• Apollomics Inc.
• Agios Pharmaceuticals Inc.
• BioMed Valley Discoveries Inc.
• Avistone Biotechnology Co. Ltd.
• NextSource Biotechnology LLC
• Sunesis Pharmaceuticals Inc.
What Is The Most Dominant Region In The LowGrade Glioma Market?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.